November is Hyperhidrosis Awareness Month

Dermira supports the hyperhidrosis community—from the more than 15 million patients in the US who suffer from excessive sweating to the advocates and healthcare professionals who care for them.



We are focused on developing important new therapies that provide meaningful benefit to patients.

Dermira is committed to identifying the unmet needs of patients living with chronic skin conditions and harnessing scientific advances to develop differentiated, novel therapies that address the needs of these patients.

With our deep insight in skin biology and our thorough understanding of unmet patient needs, we are developing a portfolio of unique therapies to elevate the standard of care for patients living with skin conditions.

Our dermatology-focused pipeline includes the following programs:

  • Pre-IND
  • Phase Ph1
  • Ph2
  • Ph3
  • Filed
  • Approved
Qbrexza® (glycopyrronium) cloth for primary axillary hyperhidrosis
  • Approved
Lebrikizumab Injectable α-IL-13 for atopic dermatitis
  • Ph3
Early Research Programs MOA undisclosed for dermatologic diseases
  • Pre-IND

For more information about Qbrexza, please visit the Our Medicines page or

The safety and efficacy of Lebrikizumab has not been established. Lebrikizumab has not been approved by the U.S. Food and Drug Administration or other regulatory authorities.